Zeta ZAP-70 Antibody. Zeta’s recombinant mouse antibody recognizes ZAP-70, a 70 kD protein tyrosine kinase found in T-cells and natural killer cells. ZAP-70 protein is expressed in leukemic cells of approximately 25% of Chronic Lymphocytic Leukemia (CLL) cases as well. ZAP-70 expression is an excellent surrogate marker for the distinction between the Ig-mutated (ZAP-70 negative) and Ig-unmutated (ZAP-70 positive) CLL subtypes and can identify patient groups with divergent clinical courses. The ZAP-70 positive Ig-unmutated CLL cases have a poorer prognosis.
ZAP-70 is an enzyme belonging to the protein tyrosine kinase family, and it plays a role in T-cell development and lymphocyte activation. ZAP-70, which is phosphorylated on tyrosine residues upon T-cell antigen receptor (TCR) stimulation, functions in the initial step of TCR-mediated signal transduction in combination with the Src family kinases, Lck and Fyn. ZAP-70 is essential for thymocyte development. Mutations in the ZAP-70 gene cause selective T-cell defect, a severe combined immunodeficiency disease characterized by a selective absence of CD8-positive T-cells.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.